2003
DOI: 10.1034/j.1600-6143.2003.00081.x
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of Prolyl-4-Hydroxylase Ameliorates Chronic Rejection of Mouse Kidney Allografts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2006
2006
2016
2016

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 45 publications
0
9
0
Order By: Relevance
“…Therefore, novel therapies for CAN are needed to promote long-term graft survival. In the renal transplantation model of B6 donor mice to BALB/c recipient mice, the grafts develop pathological abnormalities after 6 wk that resemble chronic rejection in humans (30,31), and this model has been used in preclinical study of therapy for CAN (12). Our previous study demonstrated that pharmacological intervention of ERK1/2 signaling prolongs cardiac allograft survival (56).…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, novel therapies for CAN are needed to promote long-term graft survival. In the renal transplantation model of B6 donor mice to BALB/c recipient mice, the grafts develop pathological abnormalities after 6 wk that resemble chronic rejection in humans (30,31), and this model has been used in preclinical study of therapy for CAN (12). Our previous study demonstrated that pharmacological intervention of ERK1/2 signaling prolongs cardiac allograft survival (56).…”
Section: Discussionmentioning
confidence: 99%
“…Mouse models are essential in the study of mechanisms of acute [13] and chronic kidney transplant rejection [46]. They are especially important for the investigation of the role of certain genes in transplant rejection by studying knockout, transgenic, congenic, and inbred mouse strains [7].…”
Section: Introductionmentioning
confidence: 99%
“…For example, blockade of prolyl-4-hydroxylase, a rate-limiting step in collagen biosynthesis (126,127), resulted not only in a reduction of fibrosis and graft inflammation but also in improved graft function compared with vehicle-treated controls, with no evidence of gross toxicity in the mouse (128). Inhibition of matrix metalloproteinase enzymes, regulatory enzymes in matrix degradation, ameliorate proteinuria and histology in rat kidney allografts, depending on the time course of dosing (129).…”
Section: Abrogating Matrix Deposition: Novel Approachesmentioning
confidence: 99%